Genome Editing and Engineering: From TALENs, ZFNs and CRISPRs to
Check the listing for details.
| Location | Williamsburg, Virginia US |
| Shipping | USD 0 · Flat |
| Seller |
ddubya2012
99.9% positive · 1918 feedback
|
| Listing | FixedPriceItem · Active |
| Start time | 2024-12-31T03:36:17.000Z |
| End time | 2025-01-31T03:36:17.000Z |
| Time left | P15DT10H4M58S |
| Return shipping will be paid by | Buyer |
| All returns accepted | Returns Accepted |
| Item must be returned within | 30 Days |
| Refund will be given as | Money Back |
| Binding | Hardcover |
| Book Title | Genome Editing and Engineering: From TALENs, ZFNs and CRISPRs to |
| Number of Pages | 498 Pages |
| Publication Name | Genome Editing and Engineering : from Talens, Zfns and Crisprs to Molecular Surgery |
| Language | English |
| Publisher | Cambridge University Press |
| Item Height | 1.2 in |
| Publication Year | 2018 |
| Subject | Life Sciences / Genetics & Genomics, Chemistry / General |
| Type | Textbook |
| Item Weight | 42 Oz |
| Item Length | 9.9 in |
| Author | Krishnarao Appasani |
| Subject Area | Science |
| Item Width | 7 in |
| Format | Hardcover |
Recent advances in genome editing tools using endonucleases such as TALENs, ZFNs, and CRISPRs, combined with genomic engineering technologies, have opened up a wide range of opportunities from applications in the basic sciences and disease biology research, to the potential for clinical applications and the development of new diagnostic tools. This complete guide to endonuclease-based genomic engineering gives readers a thorough understanding of this rapidly expanding field. Chapters cover the discovery, basic science, and application of these techniques, focusing particularly on their potential relevance to the treatment of cancer, and cardiovascular and immunological disease. The final section discusses the legal and ethical issues which accompany the technology. Providing authoritative coverage of the potential that genome editing and engineering have, this is an ideal reference for researchers and graduate students and those working in the biotechnology and pharmaceutical industries, as well as in a clinical setting.
